Key Points
- Phio Pharmaceuticals director Ronald Todd Plott bought 18,300 shares at $0.83 each, spending $15,189 and increasing his stake by 43.57% to 60,300 shares.
- PHIO opened at $0.81, with a market capitalization of about $9.73 million; its 52-week trading range is $0.75–$1.88.
- Analyst opinions are mixed—one Buy and one Sell—resulting in a consensus Hold rating. The company’s latest quarterly loss of $0.36 per share matched consensus expectations.
Phio Pharmaceuticals Corp. (NASDAQ:PHIO - Get Free Report) Director Ronald Plott purchased 18,300 shares of Phio Pharmaceuticals stock in a transaction that occurred on Monday, November 9th. The stock was acquired at an average cost of $0.83 per share, with a total value of $15,189.00. Following the acquisition, the director directly owned 60,300 shares in the company, valued at $50,049. This trade represents a 43.57% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Ronald Todd Plott also recently made the following trade(s):
- On Monday, September 28th, Ronald Plott purchased 5,000 shares of Phio Pharmaceuticals stock. The shares were acquired at an average price of $1.03 per share, for a total transaction of $5,150.00.
- On Wednesday, August 19th, Ronald Plott bought 15,000 shares of Phio Pharmaceuticals stock. The shares were acquired at an average price of $1.14 per share, for a total transaction of $17,100.00.
Phio Pharmaceuticals Stock Performance
NASDAQ:PHIO opened at $0.81 on Wednesday. The stock has a market capitalization of $9.73 million, a PE ratio of -0.67 and a beta of 0.93. Phio Pharmaceuticals Corp. has a fifty-two week low of $0.75 and a fifty-two week high of $1.88. The company has a fifty day moving average of $0.96 and a two-hundred day moving average of $1.08.
Phio Pharmaceuticals (NASDAQ:PHIO - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, hitting the consensus estimate of ($0.36). Research analysts forecast that Phio Pharmaceuticals Corp. will post -1.47 earnings per share for the current year.
Analyst Upgrades and Downgrades
PHIO has been the topic of several research reports. HC Wainwright reissued a "buy" rating on shares of Phio Pharmaceuticals in a research note on Wednesday, August 26th. Weiss Ratings reissued a "sell (e+)" rating on shares of Phio Pharmaceuticals in a research report on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $14.00.
View Our Latest Report on Phio Pharmaceuticals
Phio Pharmaceuticals Company Profile
(
Get Free Report)
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company's programs are designed to enhance the immune system's ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio's research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
